BioSpace News Archive

Today, the U.S. Food and Drug Administration is providing an update on its work to increase the availability of infant and specialty formula products.

Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the first quarter ended March 31, 2022.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that members of its management team will participate in the Bank of America Securities Healthcare Conference in Las Vegas, NV on Wednesday, May 11th at 7:40 pm ET.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to 15 new employees.

SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates.

Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, announced financial results for the first quarter ended March 31, 2022, and the declaration of a cash dividend of $0.07 per share to be paid on June 24, 2022, to shareholders of record as of May 27, 2022.

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that all proposed resolutions at its Annual General Meeting of Shareholders, held today at 10:00 a.m. CEST, were duly passed.

Senseonics Holdings, Inc. reported financial results for the quarter ended March 31, 2022.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2022 on Wednesday, May 18, 2022 at 8:00am ET.

Crinetics Pharmaceuticals, Inc. announced that on May 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 234,600 shares of its common stock to eight new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.